These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10709160)

  • 1. Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment.
    Karol MD; Locke CS; Cavanaugh JH
    J Clin Pharmacol; 2000 Mar; 40(3):301-8. PubMed ID: 10709160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone.
    Cavanaugh JH; Karol MD
    J Clin Pharmacol; 1996 Nov; 36(11):1064-71. PubMed ID: 8973995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin.
    Karol MD; Locke CS; Cavanaugh JH
    J Clin Pharmacol; 1999 Dec; 39(12):1283-9. PubMed ID: 10586395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
    Pan WJ; Goldwater DR; Zhang Y; Pilmer BL; Hunt RH
    Aliment Pharmacol Ther; 2000 Mar; 14(3):345-52. PubMed ID: 10735929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lansoprazole: an alternative method of administration of a capsule dosage formulation.
    Chun AH; Eason CJ; Shi HH; Cavanaugh JH
    Clin Ther; 1995; 17(3):441-7. PubMed ID: 7585848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
    Freston JW; Chiu YL; Mulford DJ; Ballard ED
    Aliment Pharmacol Ther; 2003 Feb; 17(3):361-7. PubMed ID: 12562448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
    Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
    Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
    Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.
    Müller P; Göksu MA; Fuchs W; Schlüter F; Simon B
    Aliment Pharmacol Ther; 2000 Sep; 14(9):1225-9. PubMed ID: 10971240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
    Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
    J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
    Puchalski TA; Krzyzanski W; Blum RA; Jusko WJ
    J Clin Pharmacol; 2001 Mar; 41(3):251-8. PubMed ID: 11269565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects.
    Song M; Gao X; Hang TJ; Wen AD
    Curr Ther Res Clin Exp; 2009 Jun; 70(3):228-39. PubMed ID: 24683233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of lansoprazole treatment on diazepam plasma concentrations.
    Lefebvre RA; Flouvat B; Karolac-Tamisier S; Moerman E; Van Ganse E
    Clin Pharmacol Ther; 1992 Nov; 52(5):458-63. PubMed ID: 1424419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
    Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
    Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
    Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
    Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.